PainChek Ltd. provides pain assessment solutions primarily in Australia and Europe.
Excellent balance sheet with high growth potential.
Share Price & News
How has PainChek's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PCK's share price has been volatile over the past 3 months.
7 Day Return
AU Healthcare Services
1 Year Return
AU Healthcare Services
Return vs Industry: PCK underperformed the Australian Healthcare Services industry which returned -21.5% over the past year.
Return vs Market: PCK underperformed the Australian Market which returned -12.2% over the past year.
Price Volatility Vs. Market
How volatile is PainChek's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StSome PainChek (ASX:PCK) Shareholders Are Down 26%
2 months ago | Simply Wall StDo Insiders Own Shares In PainChek Ltd. (ASX:PCK)?
3 months ago | Simply Wall StLoss-Making PainChek Ltd. (ASX:PCK) Expected To Breakeven
Is PainChek undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: PCK (A$0.13) is trading below our estimate of fair value (A$0.41)
Significantly Below Fair Value: PCK is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: PCK is unprofitable, so we can't compare its PE Ratio to the XX Healthcare Services industry average.
PE vs Market: PCK is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PCK's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PCK is overvalued based on its PB Ratio (21.1x) compared to the AU Healthcare Services industry average (4.7x).
How is PainChek forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PCK is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).
Earnings vs Market: PCK is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: PCK's is expected to become profitable in the next 3 years.
Revenue vs Market: PCK's revenue (100.3% per year) is forecast to grow faster than the Australian market (4.1% per year).
High Growth Revenue: PCK's revenue (100.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PCK's Return on Equity is forecast to be low in 3 years time (16.6%).
How has PainChek performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PCK is currently unprofitable.
Growing Profit Margin: PCK is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: PCK is unprofitable, and losses have increased over the past 5 years at a rate of 23% per year.
Accelerating Growth: Unable to compare PCK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PCK is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (-1.5%).
Return on Equity
High ROE: PCK has a negative Return on Equity (-193.76%), as it is currently unprofitable.
How is PainChek's financial position?
Financial Position Analysis
Short Term Liabilities: PCK's short term assets (A$6.9M) exceed its short term liabilities (A$822.6K).
Long Term Liabilities: PCK has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: PCK is debt free.
Reducing Debt: PCK has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PCK has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if PCK has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is PainChek current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PCK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PCK's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PCK's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PCK's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PCK's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Philip Daffas, BSc, Dip EENG, MBA, GAICD, has been Managing Director and Director at PainChek Ltd. since September 30, 2016 and serves as its Chief Executive Officer. Mr. Daffas served as Vice Presiden ...
CEO Compensation Analysis
Compensation vs Market: Philip's total compensation ($USD270.51K) is about average for companies of similar size in the Australian market ($USD268.72K).
Compensation vs Earnings: Philip's compensation has been consistent with company performance over the past year.
|MD. CEO & Director||3.92yrs||AU$377.50k||1.98% |
|CFO & Company Secretary||3.92yrs||AU$122.83k||no data|
|Chief Technology Officer||3.33yrs||no data||no data|
|Chief Scientific Officer||no data||no data||no data|
|Head of Business Development ANZ||no data||no data||no data|
|Head of Business Development UK||0.92yr||no data||no data|
Experienced Management: PCK's management team is considered experienced (3.6 years average tenure).
|MD. CEO & Director||3.92yrs||AU$377.50k||1.98% |
|Non-Executive Chairman||3.92yrs||AU$80.00k||1.21% |
|Non-Executive Director||5.92yrs||AU$40.00k||0.94% |
|Non-Executive Director||3.92yrs||AU$40.00k||0.60% |
|Member of Clinical Advisory Board||2.17yrs||no data||no data|
Experienced Board: PCK's board of directors are considered experienced (3.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 13.3%.
PainChek Ltd.'s company bio, employee growth, exchange listings and data sources
- Name: PainChek Ltd.
- Ticker: PCK
- Exchange: ASX
- Industry: Health Care Technology
- Sector: Healthcare
- Market Cap: AU$124.307m
- Shares outstanding: 1.04b
- Website: https://www.painchek.com
- PainChek Ltd.
- 35 Lime Street
- Suite 401
- New South Wales
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|PCK||ASX (Australian Securities Exchange)||Yes||Ordinary Shares||AU||AUD||Jan 2018|
|PCK||CHIA (Chi-X Australia)||Yes||Ordinary Shares||AU||AUD||Jan 2018|
PainChek Ltd. provides pain assessment solutions primarily in Australia and Europe. The company offers PainChek, a smartphone and tablets pain assessment and monitoring device that automatically detects pa ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/08/03 10:44|
|End of Day Share Price||2020/08/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.